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Abstract: NLRP3 is associated with multiple risks in graft-versus-host disease, though unifying principles for these findings remain largely unknown. To explore the effects and mechanisms of the absence of NLRP3 function on hepatic graft-versus-host-disease, we established an allogeneic haematopoietic cell transplantation mice model by infusing bone marrow mononuclear cells and spleno-T cells of BALB/c mouse into either NLRP3-/- or wide-type C57BL/6 mice. Elevated inflammatory cell infiltration, liver fibrosis and secretions of ALT and AST together with weight loss were observed in C57BL6 recipients after transplantation. However, moderate injury pathology was detected in the liver of NLRP3-/- recipients at day 14 which gradually improved over time. Likewise, pro-inflammatory cytokine IL-1β, a downstream effecter of NLRP3 inflammasome activation, showed significantly lower expression (p < 0.05) in the liver of NLRP3-/- recipients relative to C57BL6 recipients at day 7 and day 21. Moreover, compared with C57BL6 recipients, the expression of both TNF-α and IL-1β were decreased by 3-fold and 4.7-fold, respectively, at day 21 in NLRP3-/- recipients. Interestingly, NLRP1a was expressed at a significantly reduced level in the liver of NLRP3-/- recipients (p < 0.001). Furthermore, systemic inflammation was analyzed by measuring the concentration of IL-1β and ATP in serum. The concentration of IL-1β achieved a maximum at day 14, then decreased at day 21 and day 28 in NLRP3-/- recipients. In contrast, the concentration of IL-1β in C57BL/6 recipients gradually increased from day 7 to day 28. ATP levels reduced from day 7 to day 28 in NLRP3-/- recipients, but were extremely high in C57BL6 recipients from day 14 to day 28 (p < 0.01). In conclusion, NLRP3 knockout in recipients could significantly relieve liver injury after transplantation and block the NLRP3 inflammasome pathway, thus providing a promising strategy for the treatment of GVHD prophylaxis.
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Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative approach to treat hematologic tumor, hematopoietic failure and genetic abnormality ADDIN EN.CITE , . Acute graft-versus-host disease (GVHD), which might induce rash, diarrhea, gastrointestinal hemorrhage and jaundice, impedes the development of allo-HCT due to the high death rate of transplant patients ADDIN EN.CITE , . Over 80% of transplant patients develop liver abnormalities, commonly elevated liver chemistry tests and over 40% develop hepatic GVHD, which can be fatal5.
Acute inflammation plays a critical role in liver injury. Inflammasomes, multi-molecular complexes in the cytoplasm, are responsible for triggering inflammation6. The inflammasome is formed by a member of the nucleotide-binding oligomerization domain-like receptor family pyrin (NLRPs) protein family and the adaptor protein ASC that connects the NLRPs with caspase-1 ADDIN EN.CITE , . NLRP3 inflammasome is the most well characterized inflammasome related to multiple diseases ADDIN EN.CITE 9-12. Many studies have documented that activation of the NLRP3 inflammasome requires two signals in mouse macrophages ADDIN EN.CITE , , . Microbial or endogenous molecules activate MAPK and NF-κB to induce NLRP3, pro-IL-1β and pro-IL-18 expression. Then extracellular ATP, bacterial toxins or particulate matter can directly stimulate NLRP3 and induce NLR oligomerization ADDIN EN.CITE 15. CARD from ASC protein catalyze pro-caspase-1 to mature caspase-1, then mature caspase-1 shear pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18 molecules ADDIN EN.CITE 16. Mature IL-1β is predominantly produced by macrophages, neutrophils and monocytes, which were are involved in the activation of lymphocytes and endothelial cells. Meanwhile, mature IL-18 can induce the secretion of several pro-inflammatory cytokines such as IFN-γ17. 
Allo-HCT requires myeloablation by total body irradiation (TBI) and/or chemotherapy in order to provide space in the hematopoietic compartment for the engraftment of donor hematopoietic stem cells and to prevent immunological rejection18. After conditioning therapy, pathogen-associated molecular patterns (PAMPs) such as intestinal commensal bacteria contribute to NLRP3 inflammasome-mediated IL-1β production while gastrointestinal decontamination reduces GVHD severity in the mouse allo-HCT model ADDIN EN.CITE 7. Likewise, these myeloablative conditioning regimens result in cellular damage and death that produce sterile inflammatory immune responses through the release of endogenous innate immune-stimulatory molecules referred to as damage-associated molecular patterns (DAMPs). These molecules activate specific pattern recognition receptors (PRRs) on innate immune cells, which provide the secondary signal to activate the NLRP3 inflammasome19. 
While a previous study demonstrated that closed interaction between the recipient NLRP3 single-nucleotide polymorphisms and grade 2-4 acute GVHD or extensive chronic GVHD ADDIN EN.CITE 20. 




NLRP3-/- mice (Nlrp3D301NneoR mice, B6N.129-Nlrp3tm3Hhf/J, stock number 017971) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). BALB/c mice and C57BL/6 mice, male, ages 8-10 weeks, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., China. The mice were housed in sterilized cages in a special pathogen free room at the Experimental Animal Center of Xuzhou Medical University. All procedures regarding animal care and experiments were approved by the Institutional Animal Care and Use Committee of Xuzhou Medical University and all experiments were performed according to its guidelines.
GVHD model
In BALB/c→C57BL/6 allo-HCT model, BALB/c mice were used as donors, while NLRP3-/- mice or C57BL/6 WT littermates were used as recipients, namely NLRP3-/- GVHD and C57BL/6 GVHD respectively. The recipients were fed with sterile food and acidifier water from -7 day to +7 day. Briefly, recipients were irradiated with TBI (8.5 Gy, 60Co source). Four hours after irradiation, these mice were injected intravenously with the mixture of bone marrow cells (5×106/mouse) and spleno-T cells (5×105/mouse) from BALB/c mice. Spleno-T cells were sorted from splenocytes by using a T Cell Isolation Kit (Stemcell Technologies, British Columbia, Canada). Regularly, the body weight changes and the survival time of aGVHD were recorded. Mice were sacrificed at day 7, day 14, day 21 and day 28 after transplantation. Partly fresh tissues were frozen in liquid nitrogen for mRNA preparation or western blot assay. Partly fresh tissues were fixed in 4% paraformaldehyde for hematoxylin and eosin (H&E) staining.
Flow cytometry
For detecting transplantation chimeric rate, bone marrow cells were collected when recipient mice were sacrificed at proper time, red cell lysis buffer (BD Biosciences, New Jersey, USA) was add to remove red cells. Cells were harvested and processed with antibodies as following: anti-mouse H-2Kb FITC and anti-mouse H-2Kd PE (BD Biosciences, New Jersey, USA). Stained cells were washed with iced PBS and resuspended in PBS containing 1% fetal bovine serum. The fluorescence intensity was measured by BD LSR Fortessa flow cytometer with a minimum of 50,000 events collected.
Morphology analysis
Liver specimens were fixed in 4% paraformaldehyde  and were embedded in paraffin blocks. Sections (4 μm) were subjected to standard H&E staining as previously described ADDIN EN.CITE 23. Masson staining was performed to detect collagen fiber (blue) in liver according to the protocol (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China). Manifestations of GVHD in livers were assessed based on edema and necrosis of liver cells, occlusion of hepatic vein, fibrosis of hepatic sinusoid and infiltration of inflammatory cells, referring to previous publication ADDIN EN.CITE 24.
ELISA
The concentrations of IL-1β in serum samples were detected using mouse enzyme-linked immunosorbent assay (ELISA) kits (Multi Sciences, Zhejiang, China) according to the experimental procedure.
Measurement of AST, ALT and ATP in serum
The levels of ALT and AST were detected using continuous monitoring assay with AU2700 automatic biochemical analyzer (Beckman Coulter, California, USA). And ATP was detected using chemiluminescent immunoassay with ATP assay kit (Beyotime Biotechnology, Shanghai, China). 
Western blot
Frozen liver tissues were lysed with RIPA buffer (1mM PMSF) by automatic sample rapid grinding machine (Jingxin, Shanghai, China), then incubated on ice for 30mins, and supernatants were collected after spin at maximum speed. The concentrations of proteins were detected with BCA kit (Beyotime Biotechnology, Shanghai, China). Proteins (100 μg/lane) were separated in 12% SDS-PAGE gels, transferred to nitrocellulose filter membrane (General Electric Company, England, UK) and immunoblotted overnight at 4 ℃ with appropriate primary antibodies specific for IL-1β, ASC, caspase-1, α-tubulin (Santa Cruz, California, USA). After incubating with secondary antibodies with HRP, the membranes were washed with PBST, then films were developed with ECL kit (Bio-Rad, California, USA) and photos were taken.
Quantitive Real-Time PCR
Frozen liver tissues from recipients at day 7 and day 21 after transplantation were lysed with automatic sample rapid grinding machine (Jingxin, Shanghai, China) and mRNA was extracted by Trizol (Invitrogen, Massachusetts, USA). Total RNA was reversely transcribed using the transcriptor first strand cDNA synthesis kit (Roche, Basel, Switzerland) and analyzed on Roche Light Cycler 480 with light cycler 480 SYBR Green I master (Roche, Basel, Switzerland). All data were normalized to the expression of β-actin. The primer sequences were as follows as Table 1.

Table 1. Primer sequences of Real-Time PCR
Primer	Sequences(5'-3')	NCBI#	Productsize (bp)
β-Actin F	ATGGAGGGGAATACAGCCC	NM_007393.5 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=930945786" \t "new_entrez​)	149
β-Actin R	TTCTTTGCAGCTCCTTCGTT		
IFN-γ F	GAGCCAGATTATCTCTTTCTACC	NM_008337.4 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=926657655" \t "new_entrez​)	169
IFN-γ R	GTTGTTGACCTCAAACTTGG		
IL-6 F	CAAGTCGGAGGCTTAATTACACATG	NM_001314054.1  (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=930945755" \t "new_entrez​)	72
IL-6 R	ATTGCCATTGCACAACTCTTTTCT		
IL-17 F	ATCCACCTCACACGAGGCACAA	NM_010552.3 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=142367609" \t "new_entrez​)	81
IL-17 R	AGATGAAGCTCTCCCTGGACTCAT		
TNF-α F	CCCCAAAGGGATGAGAAGTTC	NM_013693.3 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=518831586" \t "new_entrez​)	100
TNF-α R	GCTTGTCACTCGAATTTTGAGAA		
IL-18 F	ATGGAGACCTGGAATCAGAC	NM_008360.1 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=6680412" \t "new_entrez​)	90
IL-18 R	TGTCAACGAAGAGAACTTGG		
IL-1β F	TGAAGTTGACGGACCCCAAA 	NM_008361.4 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=921274059" \t "new_entrez​)	101
IL-1β R	TGATGTGCTGCTGTGAGATT 		
NLRP1a F	ACTTGCTTCGTACGTGCTCC	NM_001004142.2 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=241666420" \t "new_entrez​)	145
NLRP1a R	AAGTGGCTCAGCATGAAGGT		
NLRP12 F	TGATCCAGCTGAGGAAGTGT	NM_001033431.1 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=257468328" \t "new_entrez​)	187
NLRP12 R	ATCTTCAGCCACAGGGTACG		
Caspase-1 F	ATCTTTCTCCGAGGGTTGG	NM_009807.2 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​entrez​/​viewer.fcgi?db=nucleotide&id=86198304" \t "new_entrez​)	156
Caspase-1 R	AAGTCTTGTGCTCTGGGCAG 	　	　
Statistical Analysis




General characterization of GVHD after allo-HCT.

Figure 1 The body weights of mice in each group (A) and implantation chimera of bone marrow cells in recipients (B). The body weights were measured every other day. At day 14 after transplantation, bone marrow cells were collected, stained with anti-mouse H-2Kb (C57BL/6) and anti-mouse H-2Kd (BALB/c) and then quantified by flow cytometry. One representative chimera figure is displayed (N = 5).  ** indicates the significant relationship between NLRP3-/- GVHD group and C57BL/6 GVHD group (p < 0.01).
A GVHD model was established in C57BL/6 mice (H-2Kb) by transplantation of bone marrow cells combined with spleno-T cells from BALB/c mice (H-2Kd). To investigate the role of NLRP3 knockout in recipients after allo-HCT, we detected the body weight changes of transplanted mice and evaluated the imbedding of hematopoietic cells. Results illustrated that the mice lost weight quickly from day 8 (from 24 g to 18 g) and died during day 12 to day 15 in TBI group (Figure 1A). Compared with TBI group, mice gained weight gradually in the control group and no differences were found between normal NLRP3-/- and C57BL/6 without transplantation. Moreover, a decline in mouse weight was observed from day 0 to day 14 which gradually increased from day 14 to day 28 in GVHD mice. Clearly, NLRP3-/- GVHD mice gained more weight than C57BL/6 GVHD mice. On the other hand, flow cytometry analysis showed that bone marrow cells implanted well and there were no significant differences between NLRP3-/- GVHD (98.7% ± 0.04%) and C57BL/6 GVHD (97.8% ± 0.39%) mice at day 14 (Figure 1B). This phenomenon suggested that NLRP3-/- GVHD and C57BL/6 GVHD were successfully implanted and NLRP3 knockout reduced weight loss after allo-HCT.
Histological characterization of Liver in GVHD mice after allo-HCT
Figure 2 Histopathology of liver tissues in recipient mice of C57BL/6 GVHD and NLRP3-/- GVHD group. (A) H&E staining of liver at day 7, day 14, day 21 and day 28 after transplantation. Scale bar is 100 μm. (B) Semi-quantitative analysis of histopathology score of liver (N ≥ 4).  (C) Masson staining of liver sections at day 21. One representative Masson staining figure is displayed (N = 4). Scale bar is 200 μm. Blue, collagen fiber; Red, cytoplasm. ** indicates p < 0.01; *** indicates p < 0.001.

The liver is one of the main targets of GVHD. Normally, hyperplasia, edema, necrosis, fibrosis and lymphocytic infiltration are accompanied with hepatic GVHD. In order to investigate the histological characterization of liver after allo-HCT, we performed H&E staining at day 7, 14, 21 and 28. Results showed that the liver of C57BL/6 GVHD mice exhibited a slight cellular swelling, spotty necrosis and inflammatory cells infiltration around hepatic central veins at day 14 and aggravated liver injuries were found at day 21 and day 28. Meanwhile, a similar liver injury phenomenon was also found in NLRP3-/- GVHD mice at day 14, but it gradually improved at day 21 and day 28 (Figure 2A). Moreover, the histopathology score of liver in GVHD was analyzed at day 7 to day 28 (Figure 2B). Compared with the two GVHD groups, significant differences were found at day 21 and 28 (p < 0.01 & p < 0.001). 
In order to further analyze the liver injury especially liver fibrosis after transplantation, we utilized Masson staining for liver sections at day 21 (Figure 2C) and found that the fibrin deposited around hepatic central veins coupled with diffuse fibrosis of hepatic lobular sinus in C57BL/6 GVHD mice. However, no obvious liver fibrosis was found in NLRP3-/- GVHD mice. Obviously, NLRP3-/- recipients had an advantage over C57BL/6 recipients mice after allo-HCT due to the remarkably lower liver edema, necrosis, inflammatory infiltration and fibrosis.
The effect of NLRP3 knockout on serum AST and ALT

Figure 3 The levels of ALT and AST in serum at day 7 to day 28 after transplantation. Mice were sacrificed at proper time, fresh serum from each group was collected and frozen at -80 ℃ before detections (N ≥ 4). * indicates p < 0.05; ** indicates p < 0.01; **** indicates p < 0.0001.

AST, found in mitochondria and cytoplasm, will release into blood along with hepatic injury heavier. 

Additionally, ALT is served as a standard to evaluate liver function and is considered as the most sensitive index in liver injury by the World Health Organisation (W.H.O.). The typical concentration range of AST in SFP C57BL/6 (8 week old, male) is 131.6 U/L - 98.9 U/L and ALT is 49.7 U/L - 27.3 U/L. To determine liver function status in NLRP3-/- recipients after allo-HCT, we measured the concentrations of AST and ALT in serum at day 7, 14, 21 and 28. As shown in Figure 3, the levels of AST and ALT in C57BL/6 recipients gradually increased with the time and were significantly higher than NLRP3-/- recipients at day 21 (p < 0.05 & p < 0.01) and day 28 (p < 0.0001 & p < 0.001). These findings were in line with the liver damage demonstrated by H&E staining (Figure 2A) and Masson staining (Figure 2C). Importantly, serious liver damage and dysfunction revealed by high levels of released AST and ALT were detected in C57BL/6 recipients mice, but less liver damage and function loss were found in NLRP3-/- recipient mice at day 21 and day 28. These results suggest that loss of NLRP3 function adequately protect hepatic activity after allo-HCT.

Protein level changes of IL-1β, ASC and caspase-1 in NLRP3-/- recipients after allo-HCT


Figure 4 Protein levels of IL-1β, ASC and caspase-1 in C57BL/6 GVHD and NLRP3-/- GVHD group. The lysates of livers from each group were separated by SDS-PAGE and subjected to immunoblotting. Protein expression of IL-1β, ASC and caspase-1 at day 7 (A) and day 21 (B) is shown. (C) Relative expression for IL-1β, ASC and caspase-1 (day 7, N = 5; day 21, N = 4). Data are derived from three independent experiments.

Conventionally, NLRP3 is able to recognize exogenous PAMPs, endogenous DAMPs and response to danger signals, subsequently NLRP3 oligomerization recruits the adaptor, ASC, subsequently interacting with CARD to convert pro-caspase-1 to caspase-1, which cleave pro-IL-1β and pro-IL-18 into activated IL-1β and IL-18. In order to investigate if loss of NLRP3 function will disturb the expression of other inflammasome components, such as ASC, caspase-1 and IL-1β, western bloting was used to analyze those proteins in liver at day 7 and day 21. Results showed (Figure 4) that the IL-1β expression level in NLRP3-/- recipients was significantly low at day 7 and day 21 compared with C57BL/6 mice (p < 0.05); but the ASC and pro-caspase-1 complex did not show significant differences. Interestingly, mature-caspase-1 showed higher expression levels in NLRP3-/- than C57BL/6 recipients at day 7, but did not induce higher mature IL-1β levels. These findings indicated that loss of NLRP3 function reduced the expression of the key inflammatory effector IL-1β and hence alleviated hepatic GVHD. 

Expression of inflammasome related factors in NLRP3-/- recipients after allo-HCT based on mRNA accumulation. 

Figure 5 The mRNA levels of cytokines and inflammasome components in C57BL/6 GVHD and NLRP3-/- GVHD group. Frozen liver tissues collected at day 7 and day 21 after transplantation were lysed, extracted RNA and analysed by real-time PCR. Cytokines IFN-γ, IL-17, IL-6 and TNF-α were referred as inflammatory factors; cytokines IL-18 and IL-1β were secreted based on the activation of inflammasomes; NLRP1a, NLRP12 and caspase-1 were inflammasome components. Relative expression for these mRNAs were normalized to the expression of β-actin (day 7, N = 5; day 21, N = 4). Data are derived from at least three independent experiments.

The activation of multi-inflammatory cytokines were involved in the process of hepatic GVHD. To explore which cytokine plays a critical role in NLRP3-/- recipients and how other inflammasome components might be involved after allo-HCT, we used quantitive real-time PCR to analyze the changes of mRNA levels in liver tissues.
As shown in Figure 5, the mRNA expression of IFN-γ, IL-6 and IL-18 had no significant differences between the two groups at day 7 and day 21. Compared with C57BL/6 recipients, the IL-17 level was higher in NLRP3-/- recipients at day 7 (p < 0.05), while the expression levels of TNF-α (3 fold, p < 0.05) and IL-1β (4.7 fold, p < 0.001) were notably lower in NLRP3-/- recipients at day 21. These findings suggested that lss of NLRP3 function might impact the quantity of IL-17-producing T cells not IFN-γ-producing T cells early after allo-HCT (day 7). Moreover, TNF-α and IL-1β might be the dominated inflammatory factors regulated by loss of NLRP3 function  after allo-HCT (day 21). 
We also measured the mRNA expression levels of inflammasome related molecules. The expression level of NLRP1a in NLRP3-/- recipients was significantly lower (p < 0.001) at day 7 and day 21 compared with C57BL/6 recipients; while the expression level of NLRP12 in NLRP3-/- recipients was higher (p < 0.05) at day 7. The downstream molecule caspase-1 exhibited higher expression at day 21 than day 7 but no differences were found between the two groups at each time point. These results suggested that NLRP1a and NLRP12 might be involved in the protection of hepatic GVHD in NLRP3-/- recipients after allo-HCT and further investigation is needed.
The effect of loss of NLRP3 function on serum IL- 1β and ATP 


Figure 6 The concentration changes of IL- 1β and ATP in serum at day 7, day 14, day 21 and day 28 after transplantation. Mice were sacrificed at given times, fresh serum from each group was collected and frozen at -80 ℃ before analysis (N ≥ 4). ** indicates p < 0.01; *** indicates p < 0.001; **** indicates p < 0.0001.

GVHD was considered as a disease of multi-organs systemic inflammation after allo-HCT. The released pro-inflammatory cytokines and danger signals in serum reflected the severity of GVHD.

IL-1β is a powerful pro-inflammatory cytokine with pleiotropic activities, which play a critical role in systemic inflammation. To evaluate its role in NLRP3-/- recipients after allo-HCT, we observed the concentration of IL-1β in serum. As shown in Figure 6, the concentration of IL-1β exhibited no significant differences between NLRP3-/- GVHD and C57BL/6 GVHD group at day 7 and day 14. However, the release of IL-1β in the C57BL/6 GVHD group gradually increased from day 7 to day 28. Notably, the release of IL-1β achieved a maximum at day14, followed by a decrease at day 21 and day 28 in the NLRP3-/- GVHD group, which were consistent with the temporal changes of liver damage demonstrated by our scoring system (Figure 2B). Collectively, we speculate that in addition to liver protection, loss of NLRP3 function alleviated systemic inflammation by reducing the pro-inflammatory cytokine IL-1β after allo-HCT.
Dying cells or tissues release DAMPs which can serve as danger signals for the immune system ADDIN EN.CITE , . Previous in vitro and in vivo studies demonstrated ATP as a DAMP, which functioned as a potent activator of NLRP3-dependent IL-1β release ADDIN EN.CITE , . Therefore, we measured the ATP level in serum after allo-HCT. As shown in Figure 6, ATP levels were slightly reduced from day 7 to day 28 in NLRP3-/- recipients, while persistently elevated ATP release in C57BL6 recipients was observed after day 7. Moreover, ATP levels in NLRP3-/- recipients were significantly lower than in C57BL/C recipients from day 14 to day 28. These data demonstrated that reduced ATP release might alleviate systemic inflammation in NLRP3-/- recipients after allo-HCT.

Discussion
The inflammasome is an important factor integral to innate and adaptive immunity and both PAMPs and DAMPs are able to activate inflammasome function ADDIN EN.CITE , , . Our previous studies have reported that the NLRP3 inflammasome is the essential platform for caspase-1 activation in response to multiple distinct exogenous and endogenous stress or danger signals after HCT ADDIN EN.CITE 23. This finding is consistent with Jankovic and co-authors’ conclusions that blocking the NLRP3-inflammasome activated pathway can protect against aGVHD ADDIN EN.CITE 7. Previous studies have focused on the NLRP3 inhibitor, BAY 11-7082, but this compound can influence both NLRP3 and NF-κB pathways, hence is not suitable for our study. We therefore used NLRP3-/- mice as recipients in an allo-HCT mouse model. Our results illustrated that loss of NLRP3 function can significantly relieve hepatic GVHD and decrease the risks of liver necrosis, fibrosis and associated dysfunction.
IL-1β is a key inflammatory cytokine involved in the development of GVHD and in the outcome of allo-HCT ADDIN EN.CITE 30. Blocking  IL-1β derived from DCs and T cells can increase survival rates of transplanted mice and improve aGVHD. IL-1β, an endogenous pyrogen, is a highly inflammatory cytokine whose production is tightly controlled by the NLRP3 inflammasome ADDIN EN.CITE 31. Moreover, the NLRP3 inflammasome components NLRP3 and ASC, which are required for pro-IL-1β cleavage, are critical for the full manifestation of GVHD ADDIN EN.CITE 7. In our study, no significant decreased expression of pro-caspase-1, ASC adaptor and IL-1β was found in the NLRP3-/- GVHD group corresponding with assuasive hepatic GVHD. Whereas functional protein mature IL-1β was significantly lower, even if higher mature-caspase-1 was increased in the NLRP3-/- GVHD group (day 7) relative to the C57BL/6 GVHD group. This suggests that not only caspase-1 but also other molecules, which were down-regulated after loss of NLRP3 function in liver, might cleave pro-IL-1β into IL-1β.
Pro-inflammatory cytokines like IL-17 and TNF-α probably participate in the protection of hepatic GVHD in NLRP3-/- recipients. IL-17 can be secreted by Th17, Tc17, innate immune cells and neutrophils32. Also, IL-17 in combination with IL-22 can promote cell survival and growth and participate in the regeneration of liver, skin and intestine ADDIN EN.CITE 33. Livers exhibiting NLRP3-overexpression (NLRP3 A350V knock-in) mice typically showed severe liver inflammatory changes, which were characterized by infiltration with neutrophils, activation of inflammatory macrophages and elevated levels of IL-17 and TNF34. Compared with NLRP3-overexpression mice, knock-down of IL-17A resulted in fewer neutrophils and exhibited amelioration of liver injury. TNF knockout mice resulted in a marked decrease in circulating IL-1β levels and strikingly reduced liver inflammation. In accordance with a previous study34, we found that the expression levels of IL-17 increased at the early stage of transplantation (day 7) but no marked increase was found later (day 21) in the NLRP3-/- GVHD group, although moderate inflammatory pathology changes were shown in livers at day 21. While, the expression of TNF-α was significantly decreased at day 21 in the NLRP3-/- GVHD group corresponding with liver inflammation. This phenomenon suggests that TNF-α but not IL-17 might be the key factor in hepatic GVHD in NLRP3-/- recipients. Therefore, loss of NLRP3 function could reduce hepatic GVHD by decreasing cytokine secretion of TNF-α together with IL-1β after allo-HCT.
NLRs are the key regulators of inflammation, which are highly conserved cytosolic pattern recognition receptors35. Multi-inflammasomes contribute to host defense against bacteria (V. cholera) in vivo ADDIN EN.CITE 36. Our previous study already pointed out the expression of NLRP1a, NLRP, and NLRC4 were significantly increased in liver which indicated multi-inflammasomes were active in hepatic GVHD after transplantation ADDIN EN.CITE 22. In this study, we found the expression level of NLRP1a is significantly decreased after NLRP3 knockout. Given the domain structure of human NLRP1 is comprised of an amino-terminal pyrin domain, a centrally located NOD and LRRs, carboxy-terminal function-to-find domains and CARDs 37, we speculate that NLRP1 might share the processing of gene transcription and translation with NLRP3.
However, another receptor NLRP12 showed a significant increase at day 7 in NLRP3-/- recipients. These results were expected because NLRP12 inflammasomes play an anti-inflammatory role38, unlike NLRP3 which acts as a pro-inflammatory factor. NLRP12 inhibits the canonical NF-κB signaling pathway by preventing the accumulation of hyper phosphorylated kinase I RAK1 and noncanonical signaling via NF-κB through association with and degradation of NIK. Activation of NF-κB is a key regulator of inflammation and can be promoted through various stimuli, which result in the production of a plethora of pro-inflammatory cytokines, including TNF, IL-1β and IL-6 ADDIN EN.CITE 39. How inflammasomes and other signaling pathways work together in vivo to orchestrate innate and adaptive immune responses after allo-HCT is an important topic for further investigation. 
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